News & Updates
Filter by Specialty:
Tofacitinib shows good retention rates in PsA patients
Tofacitinib demonstrates safety and persistence in patients with psoriatic arthritis (PsA) who are mostly refractory to biologic and oral targeted synthetic disease-modifying antirheumatic drugs, results of a study have shown.
Tofacitinib shows good retention rates in PsA patients
15 Jul 2024
Statin use tied to joint replacement risk
A French study presented at EULAR 2024 reveals an association between statin treatment and an increased risk of total joint replacement in individuals with knee and hip osteoarthritis (OA).
Statin use tied to joint replacement risk
11 Jul 2024
Rituximab shows promise in management of neuropsychiatric SLE
Treatment with rituximab (RTX) in patients with moderate-to-severe neuropsychiatric (NP) systemic lupus erythematosus (SLE) appears to result in some improvements and to contribute to the use of a much lower steroid dose at 6 months, suggests a study presented at EULAR 2024.
Rituximab shows promise in management of neuropsychiatric SLE
02 Jul 2024
Novel JAK1 inhibitor relieves symptoms in active RA
Use of the selective JAK1 inhibitor SHR0302 significantly improves the clinical signs and symptoms of patients with moderate-to-severe active rheumatoid arthritis (RA) who had shown poor response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), according to a study presented at EULAR 2024.
Novel JAK1 inhibitor relieves symptoms in active RA
02 Jul 2024
Lung ultrasound helps rule out ILD in patients with RA
Lung ultrasound (LUS), a low-cost tool with a high negative predictive value, can be a useful instrument for dismissing the presence of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA), suggests a study.
